Pursuing a selective path
Cholangiocarcinoma and further research
For first-line treatment of cholangiocarcinoma
BridgeBio Pharma Expands Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBio
Ivy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics Announce Dosing of First Patient in Investigator-Initiated Phase 0/2 Clinical Trial of Infigratinib in Recurrent Glioblastoma
BridgeBio Pharma’s QED Therapeutics Doses First Child in Phase 2 Clinical Trial of the Investigational Medicine Infigratinib in Achondroplasia
Receive updates on the development of infigratinib and breaking news from QED Therapeutics.
75 Federal Street
San Francisco, CA 94107
By selecting “Proceed” you will leave QEDTx.com and be directed to an external website.